Indraprastha Medical Corporation LimitedQ1 FY27 Results & Financial Update
Indraprastha Medical Corporation Limited: Q1 FY27 standalone results and company financials – revenue ₹406.15 Cr, PAT ₹55.85 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Indraprastha Medical Corporation price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Indraprastha Medical Corporation Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Indraprastha Medical Corporation Limited recorded revenue from operations of INR 406.15 crore for the quarter ended June 30, 2026, marking an expansion from INR 365.06 crore in the corresponding period of the previous year and INR 364.81 crore in the preceding quarter ended March 31, 2026.
Total income for Q1 FY27 reached INR 414.57 crore, bolstered by other income of INR 8.42 crore, compared to total income of INR 371.96 crore in the year-ago quarter and INR 372.14 crore in Q4 FY26.
Profit before tax (PBT) for the quarter stood at INR 74.82 crore, showing growth over the INR 68.31 crore reported in Q1 FY25 and INR 55.01 crore in the preceding quarter.
Net profit after tax (PAT) for the quarter climbed to INR 55.85 crore, compared to INR 51.46 crore in the same period last year and INR 41.70 crore in the sequential fourth quarter of FY26.
Basic and diluted earnings per share (EPS) for the unannualised quarter settled at INR 6.09, compared to INR 5.61 in the corresponding quarter of the previous financial year and INR 4.55 in the immediately preceding quarter.
Total expenses for the quarter aggregated to INR 339.75 crore, compared to INR 303.65 crore in the year-ago period and INR 317.13 crore in Q4 FY26, driven by higher operational activities and clinical outlays.
Total comprehensive income for the period was recorded at INR 58.10 crore, inclusive of other comprehensive income of INR 2.25 crore net of tax expenses.
01 · Business model
What does Indraprastha Medical Corporation do?
Indraprastha Medical Corporation Limited operates healthcare facilities under the Indraprastha Apollo Hospitals brand, offering multi-specialty medical care services primarily in New Delhi, India.
The company generates its primary revenue from hospital operations, clinical services, medical diagnostics, patient care, and pharmaceutical dispensing within its single healthcare business segment.
As a standalone corporate entity without subsidiaries, joint ventures, or associate companies as of June 30, 2026, its financial results directly reflect the operational performance of its established hospital infrastructure.
The institutional economic model relies on high-acuity medical treatments, professional medical staffing, specialized surgical capabilities, and comprehensive inpatient and outpatient healthcare delivery.
02 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹406.15 Cr |
| Total income | ₹414.57 Cr |
| Profit before tax | ₹74.82 Cr |
| Profit after tax | ₹55.85 Cr |
| EPS | ₹6.09 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 13.8% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 18.4% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹8.42 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
03 · Why it moved
Why the quarter looked the way it did
What drove revenue
Revenue from operations increased to INR 406.15 crore in Q1 FY27 from INR 365.06 crore in Q1 FY25 and INR 364.81 crore in Q4 FY26, reflecting higher patient service volumes and clinical throughput.
Other income contributed INR 8.42 crore to the total income of INR 414.57 crore during the quarter, compared to INR 6.90 crore in the corresponding period of the previous year.
What drove margins
Professional charges paid to doctors formed the largest expense component at INR 111.15 crore for Q1 FY27, up from INR 97.84 crore in the year-ago quarter and INR 96.59 crore in Q4 FY26.
Cost of materials consumed stood at INR 70.13 crore, while employee benefits expense accounted for INR 72.96 crore during the quarter under review.
Other expenses were reported at INR 72.10 crore, depreciation and amortisation expense at INR 11.76 crore, and finance costs at INR 1.65 crore for Q1 FY27.
04 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
The company operates in a single primary business segment, which is Healthcare, and therefore does not provide additional segment disclosures under Ind AS 108.
05 · Strategy & new businesses
How the company is trying to change its growth mix
The company confirmed that it does not hold any subsidiary, associate, or joint venture companies as of June 30, 2026.
06 · Reported developments
What changed operationally
Quarterly net profit after tax expanded to INR 55.85 crore from INR 51.46 crore year-on-year and INR 41.70 crore sequentially.
07 · Beyond the numbers
What changed beyond the numbers
Reported update
Annual General Meeting and Dividend Record Date
The Board of Directors approved convening the 38th Annual General Meeting on September 24, 2026, through video conferencing and fixed September 18, 2026, as the record date for determining shareholders entitled to the dividend for the financial year 2025-26.
Reported update
Cost Auditor Re-appointment
The Board approved the re-appointment of M/s Devarajan Swaminathan and Co., Cost Accountants, as Cost Auditors of the company for the financial year 2026-27.
08 · Previous-quarter changes
What changed since the previous quarter
Revenue from operations increased from INR 364.81 crore in Q4 FY26 to INR 406.15 crore in Q1 FY27, while PAT rose from INR 41.70 crore to INR 55.85 crore over the same period.
09 · Key Q&A
The quarter, answered directly
What does Indraprastha Medical Corporation do?
Indraprastha Medical Corporation Limited operates healthcare facilities under the Indraprastha Apollo Hospitals brand, offering multi-specialty medical care services primarily in New Delhi, India.
What is the clearest takeaway from Q1 FY27?
Indraprastha Medical Corporation Limited recorded revenue from operations of INR 406.15 crore for the quarter ended June 30, 2026, marking an expansion from INR 365.06 crore in the corresponding period of the previous year and INR 364.81 crore in the preceding quarter ended March 31, 2026.
What drove revenue or demand?
Revenue from operations increased to INR 406.15 crore in Q1 FY27 from INR 365.06 crore in Q1 FY25 and INR 364.81 crore in Q4 FY26, reflecting higher patient service volumes and clinical throughput.
What mattered most for margins or profitability?
Professional charges paid to doctors formed the largest expense component at INR 111.15 crore for Q1 FY27, up from INR 97.84 crore in the year-ago quarter and INR 96.59 crore in Q4 FY26.
What changed operationally beyond the headline numbers?
The company confirmed that it does not hold any subsidiary, associate, or joint venture companies as of June 30, 2026.
What should the next disclosure help confirm?
The 38th Annual General Meeting scheduled for September 24, 2026.
10 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
11 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Annual General Meeting: The 38th Annual General Meeting scheduled for September 24, 2026.
- 02
Dividend Record Date: The record date of September 18, 2026, for the 2025-26 dividend distribution.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.